Paradigm Biopharmaceuticals boosts securities after convertible note conversion

Paradigm Biopharmaceuticals Limited (ASX:PAR) has applied for the quotation of an additional 5,007,627 ordinary fully paid securities. This new issuance, effective October 30, 2025, stems from the conversion of 1,000,000 convertible notes (ASX:PARAAD) on the same date. The issue price for these new securities is A$0.33 per security, with the cash consideration paid in Australian dollars.

Following this quotation, the total number of ordinary fully paid securities (ASX:PAR) on issue will rise to 428,519,176. The company also has 97,358,215 options expiring on February 11, 2026 (ASX:PAROA) and 2,500,000 options expiring on February 9, 2026, with an exercise price of A$0.65 (ASX:PARAAB). Additionally, there are 6,558,600 performance rights (ASX:PARAAC) and 2,100,000 convertible notes (ASX:PARAAD) remaining unquoted.

The new securities are expected to rank equally in all respects with the existing issued securities of the same class from their issue date. This move reflects the ongoing financial activities of Paradigm Biopharmaceuticals Limited as it manages its capital structure.